Intellia Therapeutics Inc (NTLA)
Industry Biotechnology
This stock can be held in an Investment ISA and an Investment Account
Sell
$9.04
Buy
$9.19
$-0.53 (-5.55%)
Prices updated at 13 Dec 2025, 00:59 EST
| Prices minimum 15 mins delay
Prices in USD
Intellia Therapeutics Inc is a gene editing company focused on the development of proprietary, potentially curative therapeutics utilizing a biological tool known as the CRISPR/Cas9 system.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Income statement
Year | 2023 | 2024 |
|---|---|---|
| 36m | 58m | |
| - | - | |
| -515m | -534m | |
| -1,420.51 | -923.10 | |
| -481m | -519m | |
| -506m | -524m | |
| Sales, General and administrative | 116m | 126m |
| Interest expenses | - | - |
| Provision for income taxes | - | - |
| Operating expenses | 552m | 592m |
| Income before taxes | -481m | -519m |
| Net income available to common shareholders | -481m | -519m |
| -5.42 | -5.25 | |
| Net interest income | 50m | 48m |
| Advertising and promotion | - | - |
| Net investment income, net | - | - |
| Realised capital gains (losses), net | - | - |
| Total benefits, claims and expenses | - | - |
| Earnings per share (diluted) | -5.42 | -5.25 |
| Free cash flow per share | -4.5711 | -3.7819 |
| Book value/share | 11.1553 | 9.4347 |
| Debt equity ratio | 0.092125 | 0.217846 |
Balance sheet
Year | 2023 | 2024 |
|---|---|---|
| Current assets | 998m | 640m |
| Current liabilities | 115m | 111m |
| Total capital | 1,050m | 872m |
| Total debt | 115m | 210m |
| Total equity | 1,050m | 872m |
| Total non current liabilities | - | - |
| Loans | - | - |
| Total assets | 1,301m | 1,191m |
| Total liabilities | - | - |
| Cash and cash equivalents | 227m | 189m |
| Common stock | 93m | 102m |
Cash flow
Year | 2023 | 2024 |
|---|---|---|
| Cash at beginning of period | 535m | 240m |
| Cash dividends paid | - | - |
| -408m | -355m | |
| Investments (gains) losses | -31m | 126m |
| 240m | 203m | |
| Net income | - | - |
| -394m | -349m | |
| -14m | -6m |
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.
